Company Focus
LabCorp
Latest LabCorp News
Pharmaceutical
The US Federal Trade Commission has withdraw its appeal Laboratory Corporation of America's (NYSE: LH) 2010 $57.5 million acquisition of Westcliff Medical Laboratories (The Pharma Letter December 3, 2010). Although LabCorp consummated the acquisition in June 2010, the FTC was seeking the federal court injunction to prevent LabCorp from integrating the companies pending the outcome of administrative litigation. The FTC also has withdrawn the matter from administrative adjudication - a step that stops the trial proceedings, but does not conclude the case. 28 March 2011
Related News
Insights
Company Spotlight
A biotech company developing novel therapies for autoimmune diseases by leveraging regulatory T cells (Tregs) with its next-generation cell reprogramming platform.
Latest News & Features of interest to LabCorp
Biotechnology
Pharma industry leaders at Phacilitate Advanced Therapies Europe (ATE) 2026 have this week warned that Europe must address persistent barriers to commercialization, reimbursement, manufacturing scale-up and patient access if it is to maintain its position as a global leader in cell and gene therapy. 12 September 2026
Pharmaceutical
Swiss pharma major Novartis is under public pressure to overhaul its board after two late-stage trial failures in the space of a few days triggered the steepest share price fall in the company's history. David Samra, managing director at USA-based fund manager Artisan Partners, told Reuters on Thursday that the board needs far stronger oversight of acquisitions. 11 September 2026
Biotechnology
New peer-reviewed data published in The Lancet Infectious Diseases report results from a Phase III study of 7,699 adults aged 50+ across eight countries, evaluating Australia’s CSL Ltd’s subsidiary CSL Seqirus' MF59-adjuvanted, cell-based, higher-dose quadrivalent influenza vaccine (aQIVc). aQIVc is the quadrivalent formulation of the trivalent vaccine aTIVc, and the findings of this study extrapolate to the trivalent formulation. 11 September 2026
Biotechnology
US biotech company Encoded Therapeutics has closed a $275 million series F financing that will fund pivotal testing of ETX101, a gene therapy for Dravet syndrome, a severe form of childhood epilepsy. The privately held South San Francisco firm announced the round on Wednesday, days after presenting updated trial data at the European Epilepsy Congress. 10 September 2026
Biotechnology
Bristol Myers Squibb, the US pharma major, has reported positive topline Phase II results for arlocabtagene autoleucel (arlo-cel; BMS-986393), an investigational GPRC5D-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma who had already failed four drug classes. 9 September 2026
Biotechnology
Germany-based contract development and manufacturing firm ProBioGen and French biotech Transgene announced that the companies have broadened the scope of their existing collaboration. 8 September 2026
Biotechnology
Spanish company HIPRA Human Health (HIPRA) and UK-based Accord Healthcare have announced that Bimervax LP 8.1, a protein-based COVID-19 vaccine, will be available in the UK as part of the 2026/27 autumn vaccination program through a strategic partnership between the two companies. 8 September 2026
Biotechnology
Contract development and manufacturing organization (CDMO) Northway Biotech has opened a 61 million euros ($70.8 million) Innovative Cell Therapy and Personalized Medicine Center in Vilnius, Lithuania, describing it as the first dedicated facility of its kind in the Baltic states. 4 September 2026
Pharmaceutical
The USA's Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to build the equipment needed to make individualized RNA medicines close to the patient, awarding contracts worth up to $125 million in research and development funding. 2 September 2026
Biotechnology
UK pharma major GSK presented positive Phase II data for its investigational mRNA seasonal influenza vaccine at the OPTIONS XIII Conference for the Control of Influenza on Monday, and said it intends to begin a Phase III efficacy trial this month. 2 September 2026
Latest In Brief for LabCorp
Biotechnology
UK biotech Semarion has secured $3.8 million (£2.9 million) to expand manufacturing and commercial reach of its cell-based screening technology, as it moves to convert early pharma interest into broader adoption. 31 March 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze